Both sides belong in the same article.

Anxiety

Evidence: mixed, and strongly dose-dependent.

Anxiety is one of the most common self-reported reasons for cannabis use and one of the most commonly marketed applications. The research does not support the confidence of that marketing.

The clearest finding is that THC has biphasic effects on anxiety. Low doses have been associated with reduced anxiety in some studies; higher doses reliably produce the opposite — anxiety, paranoia and in some cases panic. The threshold varies between individuals and is lower than many people expect.

This has a direct practical consequence. Someone using cannabis for anxiety who increases the dose because it is not working well enough may make the problem substantially worse. See dosage basics.

CBD has a somewhat different picture. Some studies, including work on public speaking anxiety, have reported reductions at relatively high doses. The doses used in that research are typically far above what retail CBD products deliver.

There is also a longer-term concern: regular cannabis use for anxiety may reduce anxiety acutely while worsening baseline anxiety over time, particularly with withdrawal between uses. This is not well characterized and is a recognized pattern clinically.

PTSD

Evidence: limited, with high demand.

PTSD is a qualifying condition in many state programs and a major reason for use, particularly among veterans. The evidence base has not kept pace with that.

The mechanistic rationale is genuine — the endocannabinoid system participates in fear extinction and memory processing, which is directly relevant to PTSD. See the endocannabinoid system.

Observational studies and surveys report symptom improvement, particularly for sleep and nightmares. Controlled trials are few, and results have been mixed. One notable randomised trial in veterans found cannabis was reasonably tolerated but did not show significant benefit over placebo on the primary outcome.

Sleep and nightmare improvement may be the more supportable claim than improvement in core PTSD symptoms. Detail on veteran-specific considerations in medical cannabis for older adults and veterans.

Depression

Evidence: limited, and some findings point the wrong way.

Evidence for cannabis as a treatment for depression is weak. Some observational data suggests improvement; other longitudinal research has found associations between regular cannabis use and worse depressive symptoms over time.

Disentangling direction is difficult — people with depression may use cannabis more, rather than cannabis causing depression — but the absence of supportive trial evidence is notable given how widely it is marketed for mood.

Psychosis Risk

Evidence: among the most consistent findings in the field.

This is the risk that deserves the most attention, and it is routinely omitted from consumer-facing material.

The association between cannabis use and increased risk of psychotic disorders is one of the more robust findings in cannabis epidemiology. Several features stand out:

• Dose-response. Risk increases with frequency and with potency. Daily use of high-THC products carries substantially higher risk than occasional use of lower-potency material.
• Age. Use beginning in adolescence carries higher risk than use beginning in adulthood.
• Family history. People with a family history of psychotic illness are at meaningfully higher risk.
• Population-level signal. Studies across European cities have linked availability of high-potency cannabis with rates of first-episode psychosis.

Causation is debated — the possibility that early psychosis prodrome drives cannabis use rather than the reverse has been examined seriously. The weight of evidence supports cannabis as a contributing causal factor for a subset of people, without being sufficient on its own.

The practical implication is specific rather than general. For someone with a family history of schizophrenia or bipolar disorder, or a personal history of psychotic symptoms, high-THC cannabis carries a risk that a clinician should be part of assessing.

Cannabis Use Disorder

Evidence: established.

A meaningful minority of regular users develop cannabis use disorder — difficulty controlling use, continued use despite problems, and withdrawal on stopping.

Withdrawal is real and includes irritability, sleep difficulty, decreased appetite, restlessness and low mood, typically peaking in the first week. It is not dangerous in the way alcohol withdrawal can be, and it is uncomfortable enough to drive continued use.

Risk is higher with daily use, with high-potency products, and with earlier initiation.

Why the Marketing Runs Ahead

A few reasons worth naming.

Acute effects can be genuinely pleasant, and short-term relief is easy to notice while longer-term patterns are not. Mental health conditions fluctuate naturally, which makes attribution difficult. Placebo effects in psychiatric conditions are substantial, and cannabis’s noticeable acute effects make blinding hard — see the science behind medical cannabis research. And commercially, wellness framing sells better than uncertainty.

A Reasonable Position

If you are considering cannabis for a mental health reason:

• Involve a mental health professional. Not for permission — because interactions with psychiatric medication are real and because someone should be watching for the patterns you cannot see in yourself. See cannabis and drug interactions.
• Take family history seriously. A family history of psychotic illness changes the risk calculation materially.
• Be cautious with high-THC products. Risk tracks potency across essentially every concern above.
• Do not increase the dose to fix anxiety. Biphasic effects mean that frequently makes it worse.
• Watch for escalation. Needing more over time, or difficulty going without, are signals worth acting on.
• Do not stop psychiatric medication on your own. Discontinuation effects can be serious independently of losing the therapeutic benefit.

Cannabis may help some people with some symptoms. The evidence for that is weaker than the marketing, and the risks are better documented than the benefits. Anyone telling you otherwise is not describing the research.

The post Medical Cannabis and Mental Health: What Research Says appeared first on TruMo Analytics.

That combination deserves more careful treatment than it usually gets.

Why Age Changes the Calculation

Several physiological changes matter.

Metabolism slows. Liver and kidney function decline with age, so drugs — including cannabinoids — are cleared more slowly. Effects last longer and accumulate more readily. Starting doses appropriate for a younger adult can be too high.

Body composition changes. Increased body fat relative to lean mass affects how fat-soluble compounds like cannabinoids distribute and how long they persist.

Polypharmacy. Older adults commonly take several medications, sometimes many. Every one is a potential interaction, and the risk compounds. This is the single most important consideration in this group — see cannabis and drug interactions.

Fall risk. Cannabis affects balance, coordination and blood pressure, including orthostatic hypotension. In a population where a fall can be a catastrophic event, sedation and dizziness are not minor side effects.

Cardiovascular sensitivity. THC raises heart rate, which is a more significant consideration where cardiac disease is present.

Cognitive effects. Acute cannabis effects on memory and attention may be more pronounced, and harder to distinguish from other causes, in older adults.

What the Research Says About This Group

Less than it should. Older adults have historically been underrepresented in cannabis trials, so much of what is known is extrapolated from younger populations.

Available evidence suggests older adults may be more sensitive to adverse effects — sedation, dizziness, cognitive effects — at doses that younger adults tolerate. Observational studies report symptom improvement for pain and sleep in some older patients. Dosing that starts low and increases slowly appears better tolerated, which is the general principle but matters more here.

The absence of good evidence is not evidence of harm. It is a reason for caution and monitoring rather than confidence.

Veterans

Veterans use medical cannabis at higher rates than the general population, largely for chronic pain, PTSD and sleep.

Several considerations are specific to this group.

VA care. Because cannabis remains federally controlled, VA providers cannot recommend it or complete state program paperwork. However, VA policy is that veterans should not be denied care for using cannabis, and providers can discuss it. Being open with your VA clinician is important — they need to know for interaction and treatment purposes, and it does not jeopardise your care.

PTSD evidence. Widely used for this and less well supported than the usage rate implies. Controlled trials have produced mixed results, with sleep and nightmares the more supportable claim than core symptom improvement. See cannabis and mental health.

Medication interactions. Veterans are frequently on psychiatric medications, pain medications, or both — precisely the categories where interaction risk is highest.

Missouri access. Missouri sets no separate eligibility rules for veterans or older adults, but its qualifying-conditions list ends in a catch-all that leaves the decision to the certifying provider, and a patient card runs for three years rather than annually — which matters for anyone who would rather not book a renewal appointment every year.

Palliative and End-of-Life Care

This is a distinct context where the usual calculations change.

In palliative care, the goal is comfort rather than cure, and the balance between symptom relief and long-term risk shifts accordingly. Cannabis is used in this setting for pain, nausea, appetite loss, anxiety and sleep — often several at once, which is part of its appeal where the alternative is multiple additional medications.

The evidence is limited but the clinical rationale is more straightforward: side effects that would matter over decades matter less over weeks, and quality of life is the explicit measure.

What still matters is coordination. Palliative patients are typically on complex regimens including opioids and sedatives, where additive effects are real. This should be managed by the palliative team rather than added independently.

Practical Guidance

Start much lower than standard guidance. If a typical starting dose is 2.5 mg THC, half that is a reasonable starting point for an older adult with no tolerance. Increase more slowly than you would expect to need to.

Consider CBD-dominant products first. Non-intoxicating, less likely to cause dizziness or confusion. Note that CBD carries its own interaction profile, which is not a small consideration in this group.

Take a full medication list to the appointment. Prescriptions, over-the-counter medicines, supplements, everything. A pharmacist review is worth arranging.

Prefer measurable formats. Capsules and tinctures allow exact, repeatable doses. Flower does not. See forms of medical cannabis.

First doses at home, seated, with someone present. Fall risk is the most immediate practical hazard.

Take products for someone immunocompromised seriously. Older adults, cancer patients and transplant recipients face the highest risk from fungal contamination. Verified contaminant testing is not optional here — see the risks of untested cannabis products and how to choose tested products.

Involve family or carers. Someone who can notice increased confusion, unsteadiness or sedation is a genuine safety measure.

Why Product Verification Matters More Here

An inaccurate dose is a bigger problem for a patient who is more sensitive, on more medications and at higher fall risk.

If a labeled 5 mg capsule actually contains 12 mg, the consequences for an 80-year-old on antihypertensives and a sedative are materially different from the consequences for a healthy 30-year-old.

That is the practical link between laboratory testing and this population specifically. Verified potency, verified homogeneity in infused products, and a complete contaminant panel are what make careful dosing possible at all.

Check that the batch on the packaging matches the certificate, that the date is current, and that contaminants were tested and not just potency. It takes under a minute and it matters more for this group than for any other.

The post Medical Cannabis for Older Adults and Veterans appeared first on TruMo Analytics.

Some of the beliefs behind it are demonstrably wrong. A few have something behind them, and it is worth being honest about which are which.

Where the Stigma Comes From

Cannabis was prohibited through a campaign that relied substantially on sensational press coverage and, explicitly, on the racial politics of the 1930s. The terminology itself did work — “marihuana” rather than the cannabis familiar to physicians and pharmacists.

Decades of anti-drug messaging followed, much of it presenting cannabis alongside substances with entirely different risk profiles. Generations absorbed a framework in which cannabis was categorically different from alcohol or prescription sedatives, in ways that do not survive comparison.

And enforcement made the association concrete. A criminal record attaches consequences to cannabis that no medical framework removes. The full account is in from the Marihuana Tax Act to Amendment 3 and cannabis in culture.

“Medical cannabis is just an excuse”

Mostly wrong, and revealing.

Patient survey data consistently shows chronic pain as the dominant reason for medical cannabis use, followed by conditions including anxiety, sleep problems, PTSD and the side effects of cancer treatment.

The suspicion is also selectively applied. Nobody assumes a patient prescribed opioids or benzodiazepines is pretending, despite those medications having considerably higher abuse potential. The skepticism attaches to cannabis specifically, which says more about the framing than about the patients.

That said, in a state like Missouri where a qualifying-conditions list ends in a broad catch-all and adult use is legal alongside the medical program, the boundary between medical and general adult use is genuinely blurred. Acknowledging that is not the same as dismissing patients — see medical versus recreational cannabis.

“Cannabis is a gateway drug”

Largely unsupported as stated.

The correlation exists — people who use other drugs have usually used cannabis first — but cannabis is also the most commonly used illicit substance, so this holds trivially.

Research examining causation has generally not supported the strong version. Common risk factors — trauma, mental health, environment, availability — explain much of the association. The overwhelming majority of cannabis users do not progress to other substances.

“It has no medical value”

Wrong, and frequently overcorrected.

Regulatory approval exists for cannabis-derived medicines in specific indications: purified CBD for certain severe epilepsy syndromes, and a standardized THC:CBD spray for multiple sclerosis spasticity in several countries. Synthetic cannabinoids have had approval for chemotherapy-induced nausea for decades.

The overcorrection is equally common in the other direction — treating regulatory approval for a few specific indications as validation of the whole field. Evidence is strong for a small number of conditions and thin for most. See conditions most often studied in medical cannabis research.

“Cannabis is harmless because it is natural”

Wrong, and this one comes from inside the community.

Natural origin says nothing about safety. Cannabis use disorder is real. The psychosis risk association is one of the more consistent findings in the literature. Cannabinoid hyperemesis syndrome is documented. Impairment is real, and driving under the influence is dangerous. Drug interactions are a genuine clinical concern.

Untested cannabis carries contamination risks that have nothing to do with the plant itself — mold, pesticide residue, heavy metals. See the risks of untested cannabis products.

Overstating safety damages the case for medical cannabis. Claims that do not hold up make everything else look unreliable.

“Patients are impaired all the time”

Mostly wrong.

Many medical patients use CBD-dominant products with no intoxicating effect, or use low doses, or use topicals that do not produce systemic effects at all. Patients dosing therapeutically are generally aiming for symptom relief, not intoxication, and tolerance means regular users are less impaired at a given dose than an occasional user would be.

Impairment is real when it occurs, and it is not a constant state.

Stigma From Healthcare Providers

This is the form patients report as most damaging, because it affects care.

Patients describe being dismissed, having symptoms attributed to cannabis use, or being reluctant to disclose use at all — which is the worst outcome, because the interaction risks are real and a clinician who does not know cannot manage them. See cannabis and drug interactions.

Provider hesitancy is not usually hostility. Most clinicians received no training on the endocannabinoid system or on cannabis, because it was not taught. Federal scheduling limited both research and prescribing familiarity. Some face institutional constraints.

The practical response is to find a clinician who will engage with it, and to be straightforward with the rest of your care team. See working with a qualified cannabis clinician.

Employment

Employment is where stigma has the most concrete consequences, and where patients most often have to make real trade-offs.

Missouri offers patients almost nothing here. Article XIV of the state constitution expressly bars a patient from bringing a wrongful discharge or discrimination claim against an employer for being disciplined or fired over cannabis at work, and it does not require any employer to accommodate use. There is no off-duty-use protection and no bar on pre-employment or random testing. Federal employment and federally regulated roles are further removed from any state protection.

Drug testing compounds it. Standard tests detect THC metabolites for days or weeks after use, long after any impairment has passed, so a positive result does not indicate impairment at work. That gap is a genuine unfairness and is not resolved.

What Actually Reduces Stigma

Accuracy in both directions, mostly.

Overselling cannabis creates a backlash when the claims do not hold. Understating it leaves patients unable to have a straight conversation with their clinicians. A field that describes what the evidence shows — including its limits and its risks — is more credible than one that campaigns.

Regulated testing contributes to this more than it might appear. A product with a verified certificate of analysis, from an accredited laboratory, showing exactly what it contains and what it does not, is a different kind of object from an unverified one. It moves cannabis from something you take on trust to something that has been measured — which is the same standard applied to every other regulated product.

See what cannabis lab testing is and cannabis lab testing myths.

The post Stigma and Misconceptions Around Medical Cannabis appeared first on TruMo Analytics.

Knowing how to choose cannabis products properly takes under a minute at the counter.

The Five Checks

1. Find the certificate of analysis

Every product in a regulated market has been tested batch by batch before it reached the shelf. The certificate of analysis is that record, usually accessible via a QR code on the packaging or through the retailer’s website.

If nobody can produce one, treat the product as unverified regardless of how it is packaged or described.

2. Match the batch number

This is the check most people skip and the one that most often matters.

Certificates are batch-specific. A report for a different batch — even the same cultivar from the same producer, harvested the same week — describes different material. The identifier on the packaging must appear on the report.

3. Check the dates

Look at both the sample date and the analysis date. A report from many months ago on product that has been in storage since tells you less than a recent one, particularly for microbial results.

Cannabis changes after testing. Heat, light, humidity and time all affect it, and no certificate accounts for a warehouse that ran warm. See how to store cannabis properly.

4. Confirm contaminants were tested

A potency-only certificate is not a safety document. Look for microbials, mycotoxins, heavy metals, pesticides, and — for concentrates and vapes — residual solvents.

Absence of a contaminant panel is not the same as a clean contaminant panel. See contaminant testing explained.

5. Check the laboratory

The report should name the laboratory, its license and its accreditation status. ISO/IEC 17025 accreditation means an independent body assessed technical competence, not merely that a license was issued.

A report with no identifiable laboratory behind it is not evidence.

Reading the Numbers

Total THC is calculated, not measured directly. Raw cannabis contains mostly THCA, which converts to THC when heated. Total THC accounts for that conversion and assumes it is complete — which real heating does not achieve. It is a theoretical maximum. See THC percentage explained.

Percentages and milligrams are not interchangeable. Flower and concentrates are reported as a percentage by weight; edibles and tinctures in milligrams per serving and per package.

“Not detected” is not zero. It means nothing was found above the method’s detection limit. A report that states its detection limits is telling you how strong that statement is.

Look at the full cannabinoid profile, not only total THC. The THC:CBD ratio changes a product’s character more than absolute potency does, and CBN levels indicate age or heat exposure. See cannabinoids explained.

What Higher THC Does Not Mean

Potency is a concentration measurement. It is not a quality rating, and it does not predict how a product will affect you.

It says nothing about how the material was grown or cured, about terpene content, about freshness, or about whether the product suits you. For someone with low tolerance, a very high-potency product is more likely to produce an unpleasant experience than a good one.

The market’s fixation on the THC number is also what creates commercial pressure on laboratories to report favourably — see lab ethics and data integrity.

What the Strain Name Tells You

Less than you would expect. There is no registry of cannabis cultivar names and no authority verifying claims, so the same name from two producers is frequently different material — genetically and chemically.

The indica/sativa/hybrid categories have similarly little chemical basis. See indica, sativa and hybrid explained and cannabis genetics.

The measured chemical profile is the reliable identifier. Track which profiles work for you rather than which names — names are not consistent, chemistry is.

Questions Worth Asking a Budtender

Some questions get useful answers. Others do not.

Useful:

• “Can I see the COA for this batch?”
• “When was this tested?”
• “Does this have terpene data?”
• “What is the CBD content, not just the THC?”
• “Which lab tested this?”

Less useful:

• “Which one will help my anxiety?” — a budtender is a retail employee, not a clinician, and this is a clinical question.
• “Is this indica or sativa?” — the answer carries less information than it appears to.
• “What’s your strongest?” — potency is not the useful variable for most purposes.

A dispensary that can answer the first list is one worth returning to. One that cannot produce a COA on request is telling you something.

Keeping Track

The most useful habit is also the simplest: record what you bought, the batch, the measured profile, the dose, and what happened.

After a few purchases this shows patterns that strain names never will — which cannabinoid ratios and terpene profiles actually work for you. That record is also worth bringing to a clinical appointment. See dosage basics.

If You Grow Your Own

Home-grown cannabis is untested by default. You controlled what you applied; you did not control what was in your soil, your water, or your drying room.

Many laboratories accept samples from individuals, and a home test kit is not an equivalent — kits give a rough potency estimate and do not screen for the contaminants that matter. See home kits versus laboratory testing

The One-Minute Version

Ask for the COA. Match the batch. Check the date. Confirm contaminants were tested. Check the lab is accredited.

That is the whole thing, and it puts you ahead of almost everyone else at the counter. Why it matters is in how third-party testing protects patients.

The post A Patient’s Guide to Choosing Tested Cannabis Products appeared first on TruMo Analytics.

Homemade cannabis edibles safety comes down to understanding where that uncertainty comes from.

Where the Uncertainty Comes From

1. You do not know your starting material

If your input is dispensary flower with a certificate of analysis, you at least know the potency of what you started with. If it is home-grown, trim, or material of unknown origin, you are guessing at step one — and every calculation after that inherits the error.

2. Decarboxylation is incomplete and variable

Raw cannabis contains mostly THCA, which is not intoxicating. Converting it to THC requires heat, and how completely that happens depends on temperature, time and how evenly the material was heated.

Home ovens have significant temperature variation, and thermostats are frequently off by a meaningful margin. Two people following the same instructions in different ovens get different conversion rates. See cannabinoids explained.

3. Infusion efficiency varies enormously

Cannabinoids are fat-soluble, so they are extracted into butter or oil. How much transfers depends on the fat used, the temperature, the duration, the plant-to-fat ratio and the technique.

Published infusion efficiencies vary widely, and a home cook has no way to know where in that range their batch landed.

4. Distribution is uneven

This is the one that causes the worst outcomes.

Even if the total cannabinoid content of a batch were known, it is not distributed evenly unless the mixture was thoroughly homogenized. In a tray of brownies, one piece can contain several times what another does.

Commercial producers address this with industrial mixing and verify it with homogeneity testing across multiple units from a run. A mixing bowl and a spatula do not achieve the same thing. This is precisely why edibles are tested differently from flower.

Why the Delay Makes It Worse

Ingested cannabis takes 30 minutes to two hours to take effect, sometimes longer, and lasts four to eight hours or more.

That delay is the mechanism behind most unpleasant experiences. Nothing happens, so a second dose goes in, and then both arrive together. With an unknown starting dose and uneven distribution, the result can be several times what was intended.

Ingestion also involves different metabolism — THC is converted in the liver to 11-hydroxy-THC, which is more potent and longer-lasting. An edible dose does not feel like a slower version of an inhaled dose; it feels different. See forms of medical cannabis.

Reducing the Risk

Start with material you have a COA for. Known input potency removes the largest single unknown.

Use an oven thermometer. Not the dial. Decarboxylation is temperature-sensitive and oven thermostats are frequently wrong.

Mix thoroughly and for longer than feels necessary. Uneven distribution is what turns a moderate batch into a dangerous one.

Make small, uniform portions. Individually portioned items — a mold rather than a tray — distribute more evenly than something you cut afterwards.

Assume you overshot. Estimate the dose, then start with a fraction of what you calculated. Wait two hours before any more. This single rule prevents most bad outcomes.

Test a small amount first, on a day when it does not matter. Then treat that as your reference for the batch — but only for that batch.

Write down what you did. Material, quantity, decarb temperature and time, infusion method, yield, portion count. Without a record you cannot reproduce a good result or diagnose a bad one.

Storage and Labeling

This is where homemade edibles cause harm to people who did not choose to consume them.

Commercial edibles carry child-resistant packaging and clear labeling because both are required. Homemade ones look exactly like food, because they are food.

• Label everything — what it is, estimated strength, date.
• Store separately from ordinary food, in a container that does not look like a snack.
• Keep it locked or genuinely out of reach of children. Pediatric cannabis exposures rose sharply as edibles became common, and the majority involve products that were accessible at home.
• Keep it away from pets. THC is considerably more dangerous for dogs than for people, and chocolate compounds the risk. See cannabis and pets.
• Refrigerate perishable items. An infused food is still food, with the same spoilage rules.

Food Safety Still Applies

An infused product is subject to everything that applies to the underlying food. Dairy-based items spoil. Anything containing eggs has the usual considerations. Infused oils stored improperly go rancid.

Cannabinoids also degrade — THC oxidises to CBN with heat, light and time — so a batch stored for months is not the same as it was when made.

When Someone Takes Too Much

It is unpleasant and, in adults, generally not dangerous. What usually helps: a quiet place, reassurance, water, and time. Effects peak and pass.

Seek medical help for severe symptoms — chest pain, difficulty breathing, persistent vomiting, loss of consciousness — and always for a child, an older adult, or anyone with a cardiac condition. Be straightforward with medical staff about what was taken. They need the information to treat, and withholding it delays care.

The Honest Comparison

Commercial edibles are tested for potency per serving and per package, checked for homogeneity across the batch, screened for contaminants, and labeled accordingly. Homemade edibles are none of those things.

That is not an argument against making them. It is an argument for treating an unknown dose as an unknown dose — starting very low, waiting properly, and labeling and storing them as though someone else might find them. Because someone might.

See dosage and administration basics and the risks of untested cannabis products.

The post Homemade Edibles: Dosing, Safety and Unpredictable Potency appeared first on TruMo Analytics.

The effective dose varies enormously between individuals. The relationship between dose and effect is not linear — more is not reliably more, and for some effects it reverses. And the delivery route changes both how much reaches the bloodstream and what form it arrives in.

Understanding medical cannabis dosage starts with accepting that there is no standard dose, only a process for finding yours.

Why Individual Variation Is So Wide

Several factors compound.

Tolerance. Regular THC exposure downregulates CB1 receptors. An experienced user may need several times what a new user does for a comparable effect, and tolerance builds faster than most people expect.

Physiology. Endocannabinoid systems differ between people in receptor density, enzyme activity and baseline signalling. Genetic variation in the enzymes that metabolise cannabinoids affects how long effects last. See the endocannabinoid system.

Route. Inhaled cannabinoids reach the bloodstream directly. Ingested cannabinoids pass through the liver first, where THC is converted to 11-hydroxy-THC — more potent and longer-acting. That is why an edible feels different from an inhaled dose, not just slower.

Body composition and what else is in your system. Cannabinoids are fat-soluble and distribute accordingly. Food affects absorption of ingested products substantially.

Biphasic Effects: Why More Can Be Worse

This is the point most commonly missed, and it explains a lot of bad experiences.

Several cannabis effects are biphasic — the direction reverses at higher doses. Low doses of THC are often reported as anxiety-reducing; higher doses frequently produce anxiety and paranoia. The same pattern appears for some other effects.

The practical implication is that someone who takes more because a lower dose did not work well enough may get a worse outcome rather than a stronger one. If a dose is producing an unwanted effect, increasing it is often the wrong response.

Start Low, Go Slow — in Actual Numbers

The standard guidance is sound. What it means concretely:

Ingested products (edibles, capsules, beverages). A common starting point for someone with no tolerance is 2.5 mg of THC or less. Wait at least two hours — preferably longer — before considering more. Increase in small increments across separate sessions, not within one.

Sublingual (tinctures). Similar starting range, with faster onset. Tinctures allow the finest adjustment, which is why they suit patients working out what they need.

Inhaled. One small inhalation, then wait 10 to 15 minutes before another. Effects arrive fast enough to judge as you go, which makes this the most self-correcting route.

CBD-dominant products are generally used at considerably higher milligram doses than THC, and the effective range is less well established.

Two sessions at the same dose tell you more than one session at each of two doses. Consistency is what makes the information usable.

The Two Mistakes That Cause Most Problems

Redosing edibles too early. This causes more unpleasant experiences than anything else in cannabis. Nothing happens for 45 minutes, so a second dose goes in, and then both arrive together. Two hours is the minimum wait. Set a timer if necessary.

Assuming a new product behaves like the last one. Different batch, different format, different producer — treat it as new and start lower than you finished. This matters particularly with concentrates and with homemade products, where potency is least predictable. See homemade edibles.

Why Verified Potency Is the Foundation

Every dosing decision rests on the label being accurate. If a 10 mg gummy actually contains 4 mg, or 22 mg, the whole process breaks down.

This is where laboratory testing stops being an abstraction. Potency testing establishes cannabinoid content per unit, and for infused products, homogeneity testing establishes that units within a batch are consistent — not merely correct on average. A batch averaging 10 mg while ranging from 3 mg to 22 mg is a dosing failure that an average conceals.

For a patient titrating carefully, that variability is the difference between a working process and guesswork. Detail in why edibles are tested differently.

Keeping a Record

A simple log is the most useful dosing tool available, and almost nobody keeps one.

Record the product and batch, the form, the dose in milligrams, the time taken, when effects began, how long they lasted, what the effect was, and anything relevant about context — food, timing, other medications.

After a few weeks this shows patterns that memory does not: which products work, which do not, how much you actually need, and how timing affects the result. It also gives your clinician something concrete to work with.

Tolerance

Tolerance to THC develops with regular use, faster than many people expect, and it means an escalating dose for the same effect.

A tolerance break — a period of abstinence — allows CB1 receptor density to recover. This is well documented and is why some patients cycle deliberately rather than increasing indefinitely.

If you find yourself needing steadily more, that is worth raising with a clinician rather than simply increasing.

When to Involve a Professional

Always for the initial decision. Specifically and urgently if you take other medications — cannabinoids affect the enzymes that metabolise many drugs, which can change their levels. See cannabis and drug interactions.

Also if you have a cardiovascular condition, a psychiatric history, are pregnant or breastfeeding, are elderly or managing multiple conditions, or if effects are not what you expected in either direction.

See working with a qualified cannabis clinician, and medical cannabis for older adults where interaction risk is higher.

The Short Version

• Start lower than you think you need
• Wait longer than feels necessary, especially with edibles
• Increase in small steps across separate sessions
• Treat every new product as new
• Keep a record
• Buy products with verified potency and check the batch matches
• Tell your prescriber

The post Dosage and Administration Basics for Medical Cannabis Patients appeared first on TruMo Analytics.

Both produce the same piece of paper. Only one produces useful care.

Who Can Certify You in Missouri

In Missouri a certification must come from a physician (MD or DO) or a nurse practitioner holding a current, unrestricted Missouri license and in good standing with their board. Physician assistants are not eligible to certify.

Certifying providers register an account in the Department of Health and Senior Services online registry portal and are verified by the department before they can submit certification forms electronically. Missouri does not require certifying providers to complete cannabis-specific education or continuing medical education.

For patients there are two practical points. Confirm your provider is set up in the state portal before the appointment, and apply within 30 days of being certified — a certification more than 30 days old will not support an application. Both matter most with telehealth services, where the provider may not be who you assume.

What a Good Consultation Involves

A proper appointment covers the same ground as any other clinical consultation.

A full history. What you are dealing with, how long, what you have tried, what worked and what did not.

A complete medication review. Everything — prescriptions, over-the-counter medicines, supplements, herbal products. Cannabinoids affect the enzymes that metabolise many drugs, and this is the single most clinically important part of the appointment. See cannabis and drug interactions.

Relevant risk assessment. Cardiovascular history, because THC raises heart rate. Psychiatric history, including family history, because of the association between high-potency cannabis and psychosis risk. Substance use history. Pregnancy or breastfeeding.

A discussion of what to expect. Which formats might suit, roughly what dosing looks like, what side effects are common, and what would warrant stopping.

A follow-up plan. Cannabis is not a single-decision treatment. A clinician who does not want to hear how it went is not managing your care.

Warning Signs

Several things distinguish a certification service from clinical care.

• No medication review. The most serious omission. Interactions are the main clinical risk and this is where they would be caught.
• Approval guaranteed in advance. A clinician who has decided before assessing you is not assessing you.
• No discussion of risks. A balanced conversation includes what could go wrong.
• An appointment measured in minutes. A genuine history takes longer than that.
• No follow-up offered.
• Product recommendations tied to a specific dispensary. That is a commercial relationship, not clinical advice.

Preparing for the Appointment

You will get more out of it with a little preparation.

Bring a complete written list of every medication and supplement with doses. Bring a summary of your condition and its history — when it started, how it has progressed, what has been tried. Bring relevant records if you have them.

Write down your questions in advance. And be straightforward about any current or previous cannabis use. It is clinical information, not a confession, and withholding it leads to worse advice.

Cannabis Alongside Conventional Care

The framing that causes problems is cannabis as an alternative to conventional medicine. The framing that works is cannabis as one option within it.

In practice that means your other clinicians know about it. A cardiologist, an oncologist, a psychiatrist, a pharmacist and a GP all have reason to know, because it can affect what they prescribe and how they interpret what they see.

It also means not stopping existing treatment without discussing it. This is a real pattern and a genuinely dangerous one — patients discontinuing anticonvulsants, psychiatric medication or cardiac drugs on the basis that cannabis is working. Withdrawal effects from some medications are serious in their own right, separate from the loss of therapeutic benefit.

Pharmacists are underused here. They are the most accessible medication-interaction expertise available, and most people never ask.

Why Integration Is Harder Than It Should Be

Several structural problems get in the way.

Many physicians received no training on the endocannabinoid system or on cannabis, because it was not in the curriculum. Federal scheduling has limited both research and prescribing familiarity. Some clinicians are reluctant for professional or institutional reasons. And “recommendation” is not “prescription” — the legal framework itself keeps cannabis at arm’s length from ordinary practice.

The result is that patients often end up as the point of coordination between clinicians who are not talking to each other. That is not ideal, and being organized about it — keeping your own records, telling everyone, bringing your log — is the practical response. See dosage basics.

What Your Clinician Cannot Tell You

One gap worth naming: most clinicians cannot advise on product quality.

Whether a specific product was properly tested, what the certificate of analysis shows, whether contaminant panels were run — that is not clinical knowledge and it is not what they are trained on.

That part is on you, and it is not difficult. Check that a product has a current COA, that the batch matches, and that contaminants were tested rather than potency alone. See how to choose tested cannabis products and reading lab results.

The Point

A recommendation is a legal document. Clinical care is a relationship with someone who knows your history, reviews your medications, sets expectations and follows up.

The first is easy to obtain. The second is what actually helps, and it is worth looking for specifically.

The post Working With a Qualified Cannabis Clinician appeared first on TruMo Analytics.

The mechanism is well understood. The specifics vary by drug, dose and individual, which is why this is a conversation with a clinician rather than something to resolve from an article.

The Mechanism

Most drugs are metabolised by a family of liver enzymes called cytochrome P450, principally CYP3A4 and CYP2C9. These enzymes convert drugs into forms the body can eliminate.

Cannabinoids interact with this system. CBD in particular inhibits several of these enzymes, and THC interacts with them as well.

When an enzyme is inhibited, drugs it processes are cleared more slowly, so blood levels rise — potentially into a range that causes side effects or toxicity. Conversely, anything that induces those enzymes clears drugs faster, so levels fall and the drug may stop working.

This is the same mechanism behind the grapefruit warning on many prescriptions. Grapefruit inhibits CYP3A4, which is why it appears on so many medication labels. Cannabinoids act on the same system, more broadly.

Where the Risk Is Highest

Interactions matter most for drugs with a narrow therapeutic index — where the gap between an effective dose and a harmful one is small. For those drugs, a modest change in blood level is clinically significant.

Anticoagulants

Warfarin is the clearest documented example. Case reports describe elevated INR — a measure of how long blood takes to clot — in patients using cannabis alongside warfarin, indicating increased anticoagulation and bleeding risk.

Anyone on warfarin who uses cannabis should be having their INR monitored, and their prescriber needs to know.

Anticonvulsants

Clinically important, and complicated by the fact that some patients use cannabis specifically for seizure control.

Interactions between CBD and clobazam are well documented — CBD raises levels of clobazam’s active metabolite, which can increase sedation. Interactions with valproate have been associated with elevated liver enzymes. Other anticonvulsants have their own considerations.

This is a case where monitoring and dose adjustment by a prescriber is the answer, not avoidance or self-management.

Sedatives and CNS depressants

Benzodiazepines, opioids, sleep medications, alcohol. The interaction here is additive rather than metabolic — combined sedation, impaired coordination and, with some combinations, respiratory considerations.

The metabolic interaction may also raise levels of some of these drugs, compounding the effect.

Psychiatric medications

Antidepressants, antipsychotics and mood stabilisers are processed by the same enzyme systems. Beyond levels, there is the pharmacodynamic question — cannabis affects mood, anxiety and, in susceptible individuals, psychosis risk, which interacts with what these medications are treating. See cannabis and mental health.

Cardiovascular medications

THC raises heart rate and can affect blood pressure, which is relevant alongside antihypertensives and antiarrhythmics. Some statins are metabolised by affected enzymes.

Immunosuppressants

Tacrolimus and similar drugs have narrow therapeutic ranges and are processed by CYP3A4. For transplant patients this is a serious consideration — and transplant patients are also among those most at risk from fungal contamination in untested product. See the risks of untested cannabis products.

Chemotherapy

Many chemotherapy agents are metabolised by the same enzymes, and cannabis is frequently used for treatment-related nausea. That combination needs oncologist oversight rather than independent management.

Route Changes the Picture

How cannabis is taken affects the interaction profile.

Ingested cannabis passes through the liver before reaching general circulation, which means maximum exposure of the enzyme systems. Edibles, capsules and tinctures carry the highest interaction potential.

Inhaled cannabis enters the bloodstream through the lungs, bypassing first-pass metabolism. Interaction potential is lower, though not absent.

Topicals act locally and do not meaningfully enter systemic circulation, so interaction risk is minimal for conventional topicals. Transdermal patches are engineered to deliver systemically and are a different case.

See forms of medical cannabis.

Why Dose Consistency Matters Here

An interaction depends on how much cannabinoid is present. That makes accurate, consistent dosing part of managing interaction risk rather than a separate concern.

If a product’s actual content varies substantially from its label — or between units in the same package — the cannabinoid exposure varies with it, and so does the effect on drug metabolism. For a patient on a narrow-therapeutic-index medication, that variability is a real clinical problem.

This is one of the more direct connections between laboratory testing and patient safety. Verified potency and, for infused products, verified homogeneity are what make a dose reproducible. See why edibles are tested differently.

What to Actually Do

1. Tell every prescriber. Cannabis is a substance that affects drug metabolism. It belongs on your medication list.
2. Talk to a pharmacist. They have interaction databases, they are accessible without an appointment, and this is exactly what they are for.
3. Do not stop prescribed medication on your own. Withdrawal from some medications is dangerous independently of losing the therapeutic effect.
4. Start low and change one thing at a time. If you are adding cannabis to an existing regimen, small doses and slow increases give you and your clinician a chance to see what happens. See dosage basics.
5. Watch for signals. Unusual sedation, dizziness, confusion, bruising or bleeding, or a previously stable condition changing.
6. Keep monitoring current. If you take a medication with routine blood monitoring, keep it up and mention the cannabis.
7. Use consistent, verified products. Reproducible exposure is part of managing this.

Being Honest About What Is Unknown

The research base on cannabis drug interactions is thinner than it should be. Much of what is known comes from case reports, pharmacokinetic studies and the CBD epilepsy trials, rather than from systematic study across drug classes.

That means absence of a documented interaction is not evidence of safety — it frequently means nobody has looked. Which is an argument for more caution rather than less, and for keeping the people managing your medications informed.

See working with a qualified cannabis clinician and medical cannabis for older adults, where multiple medications make this most relevant.

The post Cannabis and Drug Interactions: What to Discuss With Your Provider appeared first on TruMo Analytics.

This is a condition-by-condition summary of where the research actually stands, written to be useful rather than promotional.

How to Read What Follows

Evidence quality varies enormously, and it is worth being explicit about the tiers:

• Strong — supported by randomised controlled trials, often with regulatory approval of a specific formulation.
• Moderate — multiple trials with consistent findings, usually modest effect sizes.
• Limited — small trials, mixed results, or observational data only.
• Preclinical — cell or animal studies. Most preclinical findings do not translate to human benefit.

The methodological reasons cannabis research is difficult — blinding problems, non-standardized interventions, regulatory barriers — are covered in the science behind medical cannabis research. They apply to everything below.

Chemotherapy-Induced Nausea and Vomiting

Evidence: strong.

Among the best-established indications. Synthetic cannabinoid medications have held regulatory approval for this for decades, supported by trials showing benefit compared with older antiemetics.

Newer antiemetic drugs have changed the clinical picture, and cannabinoids are generally considered where conventional options have not worked adequately. Nonetheless this remains the clearest case in the field.

Severe Epilepsy Syndromes

Evidence: strong, for specific syndromes and a specific formulation.

A purified pharmaceutical CBD formulation holds regulatory approval for Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex, supported by randomised controlled trials showing reduced seizure frequency.

Two qualifications matter. This applies to a specific purified formulation at specific doses under medical supervision, not to CBD products generally. And clinically important interactions exist — with clobazam in particular — which is why this requires prescriber oversight. See cannabis and drug interactions.

The case that drove attention to this area is covered in Charlotte Figi and the turning point for CBD.

Multiple Sclerosis Spasticity

Evidence: strong to moderate.

A standardized THC:CBD oromucosal spray is approved in several countries for spasticity in multiple sclerosis where other treatments have not worked. Trial evidence supports improvement in patient-reported spasticity, with more modest effects on objective measures.

Chronic Pain

Evidence: moderate, with modest effect sizes.

The most studied indication and the most common reason people use medical cannabis.

Systematic reviews generally find that cannabinoids produce a modest reduction in chronic pain compared with placebo, with the clearest signal in neuropathic pain. The effect is real and smaller than the marketing suggests — reviews typically describe a small number of patients achieving meaningful pain reduction who would not have on placebo.

Evidence is weaker for other pain types, and long-term effectiveness data is limited. Side effects — dizziness, sedation, cognitive effects — cause a meaningful proportion of trial participants to discontinue.

The Opioid Question

Evidence: limited and contested.

The proposition that cannabis reduces opioid use has attracted considerable attention, and the evidence is more ambiguous than either side presents.

Some ecological studies found lower opioid prescribing or overdose rates in states with medical cannabis laws. Later analyses over longer periods produced different results, and this type of study cannot establish causation at the individual level.

Observational studies of patients report reduced opioid use after starting cannabis. These rely on self-report and lack control groups.

Controlled trials directly testing cannabis as an opioid-sparing intervention are few, and results are mixed.

A fair summary: plausible, of real public health interest, and not established. It should not be presented to patients as a demonstrated route off opioids, and opioid tapering should be managed clinically regardless.

Addiction and Substance Use

Evidence: limited.

Research has examined cannabinoids — CBD particularly — in the context of substance use disorders, with some small studies suggesting reduced cue-induced craving in opioid and tobacco use.

These are early findings. Cannabis itself also carries dependence potential, with cannabis use disorder affecting a meaningful minority of regular users, which complicates the framing.

Gastrointestinal Conditions

Evidence: limited.

Cannabinoid receptors are present throughout the gastrointestinal tract, and the endocannabinoid system participates in gut motility and inflammatory signalling — a plausible mechanism.

Small trials in Crohn’s disease have reported symptomatic improvement and, notably, generally without corresponding improvement in objective markers of inflammation. That distinction matters: feeling better and having less disease activity are different outcomes, and cannabis appearing to deliver the first without the second is a real finding rather than a technicality.

Evidence in ulcerative colitis and irritable bowel syndrome is thinner.

Worth noting the opposite direction too: cannabinoid hyperemesis syndrome — cyclical severe vomiting in some heavy long-term users — is well documented and frequently misdiagnosed for years.

Parkinson’s Disease

Evidence: limited to preclinical.

Interest here comes from the endocannabinoid system’s role in motor control. Some small studies and survey data report improvements in tremor, sleep and anxiety among people with Parkinson’s using cannabis.

Controlled trial evidence is sparse, and results have not consistently shown improvement in motor symptoms. Effects on non-motor symptoms such as sleep and anxiety may be more promising than effects on the movement disorder itself. Interactions with Parkinson’s medications are an additional consideration.

Glaucoma

Evidence: understood, and largely negative in practice.

This one deserves precision because it is widely misunderstood.

THC does reduce intraocular pressure — that is established and has been known since the 1970s. The problem is duration: the effect lasts only a few hours. Managing glaucoma requires continuous pressure control, which would mean dosing every three to four hours around the clock, indefinitely, with the associated intoxication and tolerance.

Professional ophthalmology bodies have generally concluded that cannabis is not a practical glaucoma treatment and that established medications are more effective and far more manageable. Relying on cannabis instead of prescribed treatment risks irreversible vision loss.

Cancer

Evidence: strong for some symptom management; preclinical only for anti-tumour claims.

This distinction is the most important on the page.

For symptoms and treatment side effects — nausea and vomiting from chemotherapy, appetite loss, pain — there is reasonable supporting evidence, as above.

For treating cancer itself — the evidence is preclinical. Laboratory studies have shown cannabinoids affecting cancer cells in culture and in animal models. This has not translated into human trials showing that cannabis treats cancer.

Preclinical results are how research begins, and the large majority of compounds that kill cancer cells in a dish never become treatments. Presenting this work as evidence that cannabis treats cancer is not supported, and patients declining or delaying conventional treatment on that basis is a documented and serious harm.

Reproductive and Menstrual Conditions

Evidence: very limited.

Cannabis has a long history of use for menstrual pain, and cannabinoid receptors are present in reproductive tissue. Survey data indicates substantial use for menstrual pain, endometriosis and menopausal symptoms.

Controlled trial evidence is close to absent. Historical use and biological plausibility are reasons to study something, not substitutes for having studied it.

Use during pregnancy and breastfeeding is a separate matter, where the evidence that does exist raises concerns and professional guidance advises against it.

What This Adds Up To

A small number of indications with genuine trial support. A larger number where the research is early, mixed or absent. And a persistent gap between what is marketed and what has been shown.

None of that means cannabis does not help people. It means that for most conditions, we do not have the evidence to say how much, for whom, or at what dose — and that honest uncertainty is more useful than confident claims in either direction.

If you are considering medical cannabis, the productive step is a conversation with a clinician who knows your history and your medications. See working with a qualified cannabis clinician, understanding medical cannabis, and cannabis and mental health.

The post Conditions Most Often Studied in Medical Cannabis Research appeared first on TruMo Analytics.

This is a plain-language starting point — what medical cannabis is, how the products differ, and what to take seriously.

What Medical Cannabis Is

Medical cannabis is cannabis used under a physician’s recommendation for a health reason, within a state program that licenses patients and regulates the supply chain.

The plant is the same plant sold recreationally in states with adult-use programs. What differs is the legal framework — registration, purchase limits, tax treatment, and in some places testing and labeling requirements. See medical versus recreational cannabis.

In Missouri there is a list of qualifying conditions, but it ends with a catch-all. The certifying provider decides whether cannabis is appropriate, using the same clinical judgment applied to any other treatment.

The Compounds That Matter

Cannabis produces over a hundred cannabinoids. Two dominate the conversation.

THC is the intoxicating compound. It is responsible for the “high” and for most of cannabis’s psychoactive effects, positive and negative.

CBD is not intoxicating. It interacts with the body differently and is the compound behind most non-intoxicating products.

The ratio between them changes a product’s character more than the absolute potency does. A high-THC, low-CBD product behaves differently from a balanced one at the same total cannabinoid content.

Terpenes — the aromatic compounds behind a cultivar’s smell — are the other half of a chemical profile. Whether they meaningfully change effects is less settled than marketing suggests, and we cover it honestly in terpenes and the entourage effect. Full detail on the compounds in cannabinoids explained.

Forms, and Why the Difference Matters

The form determines how quickly something takes effect, how long it lasts, and how predictable it is. This matters more than which cultivar you choose.

Inhaled — flower, vapes, concentrates. Effects begin within minutes and typically last two to four hours. The fast onset makes it easier to judge, because you can tell reasonably quickly whether you have had enough.

Ingested — edibles, capsules, beverages. Onset takes 30 minutes to two hours, sometimes longer, and effects last four to eight hours or more. The delay is the single most common cause of unintended overconsumption: someone takes more because nothing has happened yet, then both doses arrive together.

Sublingual — tinctures held under the tongue. Intermediate onset, and dosing is easier to control precisely.

Topical — creams and balms. Act locally and do not produce intoxication, because cannabinoids do not readily cross intact skin into the bloodstream.

Full breakdown in forms of medical cannabis and how they are used.

Reading a Label

The numbers are not intuitive. Three things are worth understanding.

Total THC is a calculated figure. Raw cannabis contains mostly THCA, which is not intoxicating and converts to THC when heated. Total THC accounts for that conversion and assumes it is complete — which real-world heating does not achieve. It is a theoretical maximum. See THC percentage explained.

Percentages and milligrams answer different questions. Flower and concentrates are labeled as a percentage by weight. Edibles and tinctures are labeled in milligrams per serving and per package. They are not interchangeable.

Higher is not better. Potency is a concentration measurement, not a quality rating. For someone new to cannabis, a high-potency product is more likely to produce an unpleasant experience than a good one.

The Certificate of Analysis

This is the part most people ignore and the part that actually tells you something.

Every product in a regulated market has been tested batch by batch by a licensed laboratory before it reached the shelf. The certificate of analysis records what was found: cannabinoid content, and whether contaminants — pesticides, heavy metals, mold, mycotoxins, residual solvents — were within limits.

Ask for it. Check that the batch number on the packaging matches the report, that the date is recent, and that contaminants were tested rather than potency alone. It takes under a minute and it is the only objective information available about a product.

How to do it is in how to choose tested cannabis products, and how to read the report in reading lab results.

Starting Sensibly

The standard guidance — start low, go slow — exists because the common mistakes are predictable.

Begin with a low dose and wait long enough to know what it does. With edibles that means at least two hours before considering more; this single point prevents most bad first experiences. Choose a setting where feeling unwell would not be a problem. Keep a simple record of what you took, how much, and what happened, because that record is what makes the next decision better.

And tell your prescriber. Not for approval — because cannabinoids affect how the body processes other medications, which is a genuine clinical consideration. See cannabis and drug interactions.

Dosing detail is in dosage and administration basics.

The Risks, Stated Plainly

A source that lists only benefits is selling something. The documented risks:

• Impairment. Cannabis affects coordination, reaction time and judgment. Do not drive.
• Anxiety and paranoia. Common with higher THC doses, and one of the most frequent reasons people have a bad first experience.
• Dependence. A meaningful minority of regular users develop cannabis use disorder.
• Psychosis risk. The association with high-potency use, particularly in adolescence and in people with family history, is one of the more consistent findings in the literature.
• Cannabinoid hyperemesis syndrome. Cyclical severe vomiting in some heavy long-term users, frequently misdiagnosed for years.
• Drug interactions. Real, and worth discussing with whoever manages your medications.
• Cardiovascular effects. THC raises heart rate, which matters for some patients.

Mental health specifically is covered in cannabis and mental health. The beliefs patients most often encounter from other people — and which of them hold up — are in stigma and misconceptions around medical cannabis.

What the Evidence Actually Supports

Medical cannabis is neither a panacea nor an empty claim.

Evidence is reasonably strong for chemotherapy-induced nausea, for specific severe epilepsy syndromes, for multiple sclerosis spasticity, and — with modest effect sizes — for some types of chronic pain. It is weaker or preliminary for most other applications, including several that are heavily marketed.

Weak evidence means the question has not been answered well, not that the answer is no. That distinction runs through conditions most often studied in medical cannabis research and the science behind medical cannabis research.

Where to Go Next

If you are starting out: read forms of medical cannabis to understand the product categories, dosage basics before your first purchase, and choosing tested products before you walk into a dispensary.

Then talk to a clinician who knows your history. That conversation is worth more than any article, including this one. See working with a qualified cannabis clinician.

The post Understanding Medical Cannabis: A Beginner’s Guide appeared first on TruMo Analytics.